Skip to main content
Top
Published in: BMC Cancer 1/2016

Open Access 01-12-2016 | Case report

A case of extragastrointestinal stromal tumor complicated by severe hypoglycemia: a unique presentation of a rare tumor

Authors: Zeb Saeed, Solaema Taleb, Carmella Evans-Molina

Published in: BMC Cancer | Issue 1/2016

Login to get access

Abstract

Background

Non-Islet Cell Tumor Hypoglycemia (NICTH) is a rare paraneoplastic cause of hypoglycemia arising from excess tumor production of insulin-like growth factor. The objective of this report is to describe an unusual case of Extragastrointestinal Stromal Tumor (EGIST) associated NICTH.

Case presentation

A 64 year-old African female was brought to the emergency room with a 1-month history of recurrent syncope, weight loss, and abdominal bloating. Serum blood glucose was discovered to 39 mg/dL, when insulin, proinsulin, and C-peptide were suppressed. Computed tomography scan revealed a diffuse extraintestinal metastatic disease process, and a biopsy confirmed the diagnosis of an Extragastrointestinal Stromal Tumor (EGIST). IGF-I and II levels were 27 ng/ml and 262 ng/ml respectively, and the ratio of IGF-II to IGF-I was calculated as 9.7:1, suggestive of IGF-II-mediated NICTH. Acutely, the patient’s hypoglycemia resolved with dextrose and glucagon infusion. Long-term euglycemia was achieved with prednisone and imatinib therapy.

Conclusions

NICTH should be considered when hypoglycemia occurs in the setting of low serum insulin levels. Whereas definitive treatment of EGIST involves surgical resection, immunotherapy with tyrosine kinase inhibitors and corticosteroids have been shown to alleviate hypoglycemia in cases where surgery is delayed or not feasible.
Literature
1.
go back to reference Iglesias P, Diez JJ. Management of endocrine disease: a clinical update on tumor-induced hypoglycemia. Eur J Endocrinol. 2014;170(4):R147–57.CrossRefPubMed Iglesias P, Diez JJ. Management of endocrine disease: a clinical update on tumor-induced hypoglycemia. Eur J Endocrinol. 2014;170(4):R147–57.CrossRefPubMed
2.
go back to reference de Groot JW, Rikhof B, van Doorn J, Bilo HJ, Alleman MA, Honkoop AH, et al. Non-islet cell tumour-induced hypoglycaemia: a review of the literature including two new cases. Endocr Relat Cancer. 2007;14(4):979–93.CrossRefPubMed de Groot JW, Rikhof B, van Doorn J, Bilo HJ, Alleman MA, Honkoop AH, et al. Non-islet cell tumour-induced hypoglycaemia: a review of the literature including two new cases. Endocr Relat Cancer. 2007;14(4):979–93.CrossRefPubMed
3.
go back to reference Walter HN, John AW. Hepatogenic hypoglycemia associated with primary liver cell carcinoma. Arch Intern Med (Chic). 1929;44(5):700.CrossRef Walter HN, John AW. Hepatogenic hypoglycemia associated with primary liver cell carcinoma. Arch Intern Med (Chic). 1929;44(5):700.CrossRef
4.
go back to reference Kumar AS, Padmini R, Veena G, Murugesan N. Extragastrointestinal stromal tumour of the abdominal wall - a case report. J Clin Diagn Res. 2013;7(12):2970–2.PubMedPubMedCentral Kumar AS, Padmini R, Veena G, Murugesan N. Extragastrointestinal stromal tumour of the abdominal wall - a case report. J Clin Diagn Res. 2013;7(12):2970–2.PubMedPubMedCentral
5.
go back to reference Rikhof B, van Doorn J, Suurmeijer AJ, Rautenberg MW, Groenen PJ, Verdijk MA, et al. Insulin-like growth factors and insulin-like growth factor-binding proteins in relation to disease status and incidence of hypoglycaemia in patients with a gastrointestinal stromal tumour. Ann Oncol. 2009;20(9):1582–8.CrossRefPubMed Rikhof B, van Doorn J, Suurmeijer AJ, Rautenberg MW, Groenen PJ, Verdijk MA, et al. Insulin-like growth factors and insulin-like growth factor-binding proteins in relation to disease status and incidence of hypoglycaemia in patients with a gastrointestinal stromal tumour. Ann Oncol. 2009;20(9):1582–8.CrossRefPubMed
6.
go back to reference Alkhatib L, Albtoush O, Bataineh N, Gharaibeh K, Matalka I, Tokuda Y. Extragastrointestinal stromal tumor (EGIST) in the abdominal wall: case report and literature review. Int J Surg Case Rep. 2011;2(8):253–5.CrossRefPubMedPubMedCentral Alkhatib L, Albtoush O, Bataineh N, Gharaibeh K, Matalka I, Tokuda Y. Extragastrointestinal stromal tumor (EGIST) in the abdominal wall: case report and literature review. Int J Surg Case Rep. 2011;2(8):253–5.CrossRefPubMedPubMedCentral
7.
go back to reference Goukassian ID, Kussman SR, Toribio Y, Rosen JE. Secondary recurrent multiple EGIST of the mesentary: a case report and review of the literature. Int J Surg Case Rep. 2012;3(9):463–6.CrossRefPubMedPubMedCentral Goukassian ID, Kussman SR, Toribio Y, Rosen JE. Secondary recurrent multiple EGIST of the mesentary: a case report and review of the literature. Int J Surg Case Rep. 2012;3(9):463–6.CrossRefPubMedPubMedCentral
8.
go back to reference Dimofte MG, Porumb V, Ferariu D, Bar NC, Lunca S. EGIST of the greater omentum - case study and review of literature. Rom J Morphol Embryol. 2016;57(1):253–8.PubMed Dimofte MG, Porumb V, Ferariu D, Bar NC, Lunca S. EGIST of the greater omentum - case study and review of literature. Rom J Morphol Embryol. 2016;57(1):253–8.PubMed
9.
go back to reference Li ZY, Huan XQ, Liang XJ, Li ZS, Tan AZ. Clinicopathological and immunohistochemical study of extra-gastrointestinal stromal tumors arising from the omentum and mesentery. Zhonghua Bing Li Xue Za Zhi. 2005;34(1):11–4.PubMed Li ZY, Huan XQ, Liang XJ, Li ZS, Tan AZ. Clinicopathological and immunohistochemical study of extra-gastrointestinal stromal tumors arising from the omentum and mesentery. Zhonghua Bing Li Xue Za Zhi. 2005;34(1):11–4.PubMed
10.
11.
go back to reference Zapf J. Role of insulin-like growth factor (IGF) II and IGF binding proteins in extrapancreatic tumour hypoglycaemia. J Intern Med. 1993;234(6):543–52.CrossRefPubMed Zapf J. Role of insulin-like growth factor (IGF) II and IGF binding proteins in extrapancreatic tumour hypoglycaemia. J Intern Med. 1993;234(6):543–52.CrossRefPubMed
12.
go back to reference Davda R, Seddon BM. Mechanisms and management of non-islet cell tumour hypoglycaemia in gastrointestinal stromal tumour: case report and a review of published studies. Clin Oncol. 2007;19(4):265–8.CrossRef Davda R, Seddon BM. Mechanisms and management of non-islet cell tumour hypoglycaemia in gastrointestinal stromal tumour: case report and a review of published studies. Clin Oncol. 2007;19(4):265–8.CrossRef
13.
go back to reference Dynkevich Y, Rother KI, Whitford I, Qureshi S, Galiveeti S, Szulc AL, et al. Tumors, IGF-2, and hypoglycemia: insights from the clinic, the laboratory, and the historical archive. Endocr Rev. 2013;34(6):798–826.CrossRefPubMed Dynkevich Y, Rother KI, Whitford I, Qureshi S, Galiveeti S, Szulc AL, et al. Tumors, IGF-2, and hypoglycemia: insights from the clinic, the laboratory, and the historical archive. Endocr Rev. 2013;34(6):798–826.CrossRefPubMed
14.
go back to reference Li H, Li J, Li X, Kang Y, Wei Q. An unexpected but interesting response to a novel therapy for malignant extragastrointestinal stromal tumor of the mesoileum: a case report and review of the literature. World J Surg Oncol. 2013;11(1):174.CrossRefPubMedPubMedCentral Li H, Li J, Li X, Kang Y, Wei Q. An unexpected but interesting response to a novel therapy for malignant extragastrointestinal stromal tumor of the mesoileum: a case report and review of the literature. World J Surg Oncol. 2013;11(1):174.CrossRefPubMedPubMedCentral
15.
go back to reference Swalchick W, Shamekh R, Bui MM. Is DOG1 immunoreactivity specific to gastrointestinal stromal tumor? Cancer Control. 2015;22(4):498–504.PubMed Swalchick W, Shamekh R, Bui MM. Is DOG1 immunoreactivity specific to gastrointestinal stromal tumor? Cancer Control. 2015;22(4):498–504.PubMed
16.
go back to reference Escobar GA, Robinson WA, Nydam TL, Heiple DC, Weiss GJ, Buckley L, et al. Severe paraneoplastic hypoglycemia in a patient with a gastrointestinal stromal tumor with an exon 9 mutation: a case report. BMC Cancer. 2007;7:13.CrossRefPubMedPubMedCentral Escobar GA, Robinson WA, Nydam TL, Heiple DC, Weiss GJ, Buckley L, et al. Severe paraneoplastic hypoglycemia in a patient with a gastrointestinal stromal tumor with an exon 9 mutation: a case report. BMC Cancer. 2007;7:13.CrossRefPubMedPubMedCentral
17.
go back to reference Blanke CD, Demetri GD, von Mehren M, Heinrich MC, Eisenberg B, Fletcher JA, et al. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol. 2008;26(4):620–5.CrossRefPubMed Blanke CD, Demetri GD, von Mehren M, Heinrich MC, Eisenberg B, Fletcher JA, et al. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol. 2008;26(4):620–5.CrossRefPubMed
18.
go back to reference Teale JD, Marks V. Glucocorticoid therapy suppresses abnormal secretion of big IGF-II by non-islet cell tumours inducing hypoglycaemia (NICTH). Clin Endocrinol (Oxf). 1998;49(4):491–8.CrossRef Teale JD, Marks V. Glucocorticoid therapy suppresses abnormal secretion of big IGF-II by non-islet cell tumours inducing hypoglycaemia (NICTH). Clin Endocrinol (Oxf). 1998;49(4):491–8.CrossRef
19.
go back to reference Perros P, Simpson J, Innes JA, Teale JD, McKnight JA. Non-islet cell tumour-associated hypoglycaemia: 111In-octreotide imaging and efficacy of octreotide, growth hormone and glucocorticosteroids. Clin Endocrinol (Oxf). 1996;44(6):727–31.CrossRef Perros P, Simpson J, Innes JA, Teale JD, McKnight JA. Non-islet cell tumour-associated hypoglycaemia: 111In-octreotide imaging and efficacy of octreotide, growth hormone and glucocorticosteroids. Clin Endocrinol (Oxf). 1996;44(6):727–31.CrossRef
20.
go back to reference Teale JD, Wark G. The effectiveness of different treatment options for non-islet cell tumour hypoglycaemia. Clin Endocrinol (Oxf). 2004;60(4):457–60.CrossRef Teale JD, Wark G. The effectiveness of different treatment options for non-islet cell tumour hypoglycaemia. Clin Endocrinol (Oxf). 2004;60(4):457–60.CrossRef
21.
go back to reference Bourcigaux N, Arnault-Ouary G, Christol R, Perin L, Charbonnel B, Le Bouc Y. Treatment of hypoglycemia using combined glucocorticoid and recombinant human growth hormone in a patient with a metastatic non-islet cell tumor hypoglycemia. Clin Ther. 2005;27(2):246–51.CrossRefPubMed Bourcigaux N, Arnault-Ouary G, Christol R, Perin L, Charbonnel B, Le Bouc Y. Treatment of hypoglycemia using combined glucocorticoid and recombinant human growth hormone in a patient with a metastatic non-islet cell tumor hypoglycemia. Clin Ther. 2005;27(2):246–51.CrossRefPubMed
Metadata
Title
A case of extragastrointestinal stromal tumor complicated by severe hypoglycemia: a unique presentation of a rare tumor
Authors
Zeb Saeed
Solaema Taleb
Carmella Evans-Molina
Publication date
01-12-2016
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2016
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-016-2968-8

Other articles of this Issue 1/2016

BMC Cancer 1/2016 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine